141 related articles for article (PubMed ID: 31414267)
21. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Saha B; Parks RJ
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181
[TBL] [Abstract][Full Text] [Related]
23. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity.
Ieda N; Yamada S; Kawaguchi M; Miyata N; Nakagawa H
Bioorg Med Chem; 2016 Jun; 24(12):2789-93. PubMed ID: 27143132
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
26. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
[TBL] [Abstract][Full Text] [Related]
27. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration.
Wolf IM; Fan Z; Rauh M; Seufert S; Hore N; Buchfelder M; Savaskan NE; Eyüpoglu IY
Sci Rep; 2014 Sep; 4():6226. PubMed ID: 25228443
[TBL] [Abstract][Full Text] [Related]
29. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
Eyüpoglu IY; Hahnen E; Buslei R; Siebzehnrübl FA; Savaskan NE; Lüders M; Tränkle C; Wick W; Weller M; Fahlbusch R; Blümcke I
J Neurochem; 2005 May; 93(4):992-9. PubMed ID: 15857402
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Sato A; Asano T; Horiguchi A; Ito K; Sumitomo M; Asano T
Oncol Res; 2011; 19(5):217-23. PubMed ID: 21542457
[TBL] [Abstract][Full Text] [Related]
33. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
Yang XF; Zhao ZJ; Liu JJ; Yang XH; Gao Y; Zhao S; Shi S; Huang KQ; Zheng HC
Oncotarget; 2017 Jan; 8(2):3156-3169. PubMed ID: 27911270
[TBL] [Abstract][Full Text] [Related]
34. Early prediction of response to Vorinostat in an orthotopic rat glioma model.
Wei L; Hong S; Yoon Y; Hwang SN; Park JC; Zhang Z; Olson JJ; Hu XP; Shim H
NMR Biomed; 2012 Sep; 25(9):1104-11. PubMed ID: 22302519
[TBL] [Abstract][Full Text] [Related]
35. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
36. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
37. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells.
Miksiunas R; Rucinskas K; Janusauskas V; Labeit S; Bironaite D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650632
[TBL] [Abstract][Full Text] [Related]
38. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
40. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Unland R; Clemens D; Heinicke U; Potratz JC; Hotfilder M; Fulda S; Wardelmann E; Frühwald MC; Dirksen U
Anticancer Drugs; 2015 Sep; 26(8):843-51. PubMed ID: 26053276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]